Baidu
map

Breast: 年龄是乳腺癌患者预后不良的独立危险因素

2011-09-22 MedSci原创 MedSci原创

 广州中山大学肿瘤中心学者的一项回顾性病例对照研究共纳入551 例年龄≤35 岁的乳腺癌患者(Ⅰ组),将36~50 岁的乳腺癌患者作为对照(Ⅱ组)。   研究结果显示,Ⅰ组患者无病生存(DFS)期、5年DFS率和总生存(OS)率均显著低于Ⅱ组,P 值分别为0.024、<0.001 和 0.024。多因素分析显示,年龄(≤35岁)是乳腺癌患者预后不

 广州中山大学肿瘤中心学者的一项回顾性病例对照研究共纳入551 例年龄≤35 岁的乳腺癌患者(Ⅰ组),将36~50 岁的乳腺癌患者作为对照(Ⅱ组)。

  研究结果显示,Ⅰ组患者无病生存(DFS)期、5年DFS率和总生存(OS)率均显著低于Ⅱ组,P 值分别为0.024、<0.001 和 0.024。多因素分析显示,年龄(≤35岁)是乳腺癌患者预后不良的独立危险因素。相关论文于8月13日在线发表于Breast。

    MedSci分析认为,这篇文章的研究着眼于DFS和年龄,而且观察到35岁作为年龄的重要分水岭,这是主要的创新之处。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710596, encodeId=7fad1e1059694, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Dec 25 15:39:00 CST 2011, time=2011-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691789, encodeId=8ba21691e892f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Jan 26 08:39:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037151, encodeId=18f1203e151a4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Jan 18 04:39:00 CST 2012, time=2012-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351050, encodeId=24e0135105008, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488315, encodeId=252714883157f, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570870, encodeId=ab8515e087055, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710596, encodeId=7fad1e1059694, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Dec 25 15:39:00 CST 2011, time=2011-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691789, encodeId=8ba21691e892f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Jan 26 08:39:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037151, encodeId=18f1203e151a4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Jan 18 04:39:00 CST 2012, time=2012-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351050, encodeId=24e0135105008, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488315, encodeId=252714883157f, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570870, encodeId=ab8515e087055, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710596, encodeId=7fad1e1059694, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Dec 25 15:39:00 CST 2011, time=2011-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691789, encodeId=8ba21691e892f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Jan 26 08:39:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037151, encodeId=18f1203e151a4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Jan 18 04:39:00 CST 2012, time=2012-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351050, encodeId=24e0135105008, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488315, encodeId=252714883157f, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570870, encodeId=ab8515e087055, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710596, encodeId=7fad1e1059694, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Dec 25 15:39:00 CST 2011, time=2011-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691789, encodeId=8ba21691e892f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Jan 26 08:39:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037151, encodeId=18f1203e151a4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Jan 18 04:39:00 CST 2012, time=2012-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351050, encodeId=24e0135105008, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488315, encodeId=252714883157f, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570870, encodeId=ab8515e087055, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=)]
    2011-09-24 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1710596, encodeId=7fad1e1059694, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Dec 25 15:39:00 CST 2011, time=2011-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691789, encodeId=8ba21691e892f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Jan 26 08:39:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037151, encodeId=18f1203e151a4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Jan 18 04:39:00 CST 2012, time=2012-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351050, encodeId=24e0135105008, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488315, encodeId=252714883157f, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570870, encodeId=ab8515e087055, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1710596, encodeId=7fad1e1059694, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Dec 25 15:39:00 CST 2011, time=2011-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691789, encodeId=8ba21691e892f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Jan 26 08:39:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037151, encodeId=18f1203e151a4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Jan 18 04:39:00 CST 2012, time=2012-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351050, encodeId=24e0135105008, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488315, encodeId=252714883157f, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570870, encodeId=ab8515e087055, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 24 13:39:00 CST 2011, time=2011-09-24, status=1, ipAttribution=)]

相关资讯

CSCO 2011:≥4个腋下淋巴结转移乳腺癌患者的局部治疗模式及预后因素分析

  上海复旦大学附属肿瘤医院乳腺外科/乳腺癌研究所 复旦大学上海医学院肿瘤学系 殷文瑾 柳光宇 狄根红 吴炅 沈镇宙 邵志敏 陆劲松   目的:≥4个腋下淋巴结转移的乳腺癌患者具有高危复发风险。大量研究结果已证实,这类患者即使经过积极规范的治疗仍预后较差。然而,目前有关这类患者临床病理学特征的研究却并不多见。因此,本文旨在探究

卵巢切除术后激素替代治疗不增加乳腺癌风险

 宾夕法尼亚大学Abramson癌症中心的Susan M. Domchek博士在美国临床肿瘤学会(ASCO)年会上公布的一项观察性队列研究显示,有BRCA突变并接受了预防性卵巢切除术的女性仍可通过激素替代治疗(HRT)控制围绝经期症状,至少短期治疗不增加乳腺癌风险。 这项名为“外科终点的预防和观察(PROSE)”的研究从美国和欧洲20个中心招募了1,299例存在BRCA1突变(61%)

大于70岁可手术乳腺癌患者可辅助序贯化疗

  《临床乳腺癌》(Clin Breast Cancer)杂志近期发表的一项研究显示,年龄大于70岁的可手术乳腺癌患者接受每周辅助表柔比星联合紫杉醇化疗是可行的。这种疗法的安全性尚可接受,疗效令人鼓舞,应当在老年患者中进行进一步研究。   该研究从2005年到2009年前瞻性地纳入了59 例年龄大于70岁的可手术乳腺癌患者,患者术后接受了每周辅助表柔比星联合紫杉醇化

CSCO 2011:中国大陆早期乳腺癌保乳术后放射治疗的全国调查

 中国医学科学院肿瘤医院 张烨 惠周光 余子豪 李晔雄   目的:全国早期乳腺癌保乳手术的开展逐渐增加,本研究调查2009年度国内保乳术后放射治疗的实际开展情况。   方法:2009年底一份有关保乳术后放射治疗实际开展情况的调查表邮寄至中国大陆的所有登记在中华放射肿瘤学协会的放射治疗单位,对于未回复的单位2010年初再次寄发调查表,并对所有回访的调查表进

TACE联合全身化疗或延长乳腺癌术后肝转移患者生存期

 《癌症研究与临床肿瘤学杂志》(J Cancer Res Clin Oncol)7月26日在线发表的一项研究结果表明,经导管动脉内化疗栓塞(TACE)联合全身化疗(SC)或可延长乳腺癌患者乳房切除术后肝转移者的生存期。   该研究对比了44例接受TACE联合全身化疗的患者(TSC组)和43例接受全身化疗的患者(SC)的转归。   结果显示,从诊断为肝转移

NCCN PK FDA:Avastin治疗乳腺癌的存废之争

今年1月,在专家组全票支持的情况下,FDA撤销了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。而7月30日,NCCN专家组却全票(24票对0票,1票弃权)支持在转移性乳腺癌治疗指南中保留Avastin。各方表现颇值得玩味。 同时欧盟European Medicines Agency(EMA)仍然保持了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。

Baidu
map
Baidu
map
Baidu
map